Terms of Access and Use

By downloading, accessing, or viewing material from this website, you agree to the following Terms of Use. The research and analysis provided by Forensic Alpha Limited (“we”, “us”) is for informational and educational purposes only and does not constitute investment advice, a recommendation to buy, sell, or hold any security, or any other form of regulated advice. We do not have, and do not seek to establish, any position (long or short) in the securities discussed in our research.

Our reports present our independent opinions on publicly available information, including but not limited to, company disclosures and financial statements. We aim to highlight potential risks, governance issues, or accounting practices that we believe merit further consideration by market participants. You agree to conduct your own research and due diligence, and to consult your own financial, legal, tax, and other professional advisers before making any investment or business decision. Use of our research is entirely at your own risk. In no event shall Forensic Alpha Limited or any affiliated party be liable for any direct, indirect, incidental, or consequential losses arising from your use of our materials.

The information we provide is based on sources we believe to be accurate and reliable at the time of publication, but it is provided “as is” without any representation or warranty of any kind, whether express or implied, including without limitation as to accuracy, completeness, or fitness for any particular purpose. All opinions expressed are subject to change without notice, and we do not undertake to update or supplement our research.

Access to our research is intended only for persons who are professional investors, institutional investors, or otherwise qualified to receive such information under applicable laws in their jurisdiction. In the United Kingdom, this includes (but is not limited to) persons falling within one or more of the categories described in Articles 19 (Investment Professionals) and 49 (High Net Worth Companies, Unincorporated Associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. By proceeding to access our materials, you confirm that you meet the relevant criteria in your jurisdiction and are legally permitted to receive such information.

All content on this site is the intellectual property of Forensic Alpha Limited and is protected by applicable copyright laws. You agree not to reproduce, distribute, or transmit our research, in whole or in part, without our prior written consent, except by sharing a direct link to our website.

By clicking “I Agree” below, you confirm that you have read and agree to Forensic Alpha Limited’s Terms of Access and Use, that you are a professional or institutional investor (or otherwise qualified under the laws of your jurisdiction to receive such information), and that you understand our research does not constitute investment advice or a recommendation to buy, sell, or hold any security.
I Agree
back arrow

Stora Enso: Pushing the Envelope

Thomas Beevers
Thomas Beevers
May 13, 2026
Copied!
share button icon

Stora Enso: Pushing the Envelope

Stora Enso delivered a somewhat lacklustre set of full year results, as increasing fiber costs held back profitability. However, one bright spot was the impressive reduction in working capital, helping to drive strong operating cash flow and reduce gearing.

The chart on the left  here shows net debt to adjusted EBITDA moving back from a peak of 4.0x to 3.0x, towards the target of < 2.0x.  Meanwhile Operating Working Capital (“OWC”) has dropped to a record 7% of sales.

This achievement was celebrated on the earnings call, by the CFO, Niclas Rosenlew:

"When it comes to our operating working capital, we saw a clear improvement throughout the year. This was thanks to dedicated and focused actions. And the working capital ended at a record low EUR 544 million in the fourth quarter. This was actually a reduction of more than EUR 700 million since the peak some 1.5 years ago. The operating working capital to sales was 7% in Q4, actually a record low, down from 14% at the peak."

The annual report was published two days after this earnings call and provided much more precise information about the changes in working capital, which were picked up by our automated system. One revealing disclosure in the notes shows the rapid growth in the use of factoring arrangements (see extract below). This shows a substantial increase in receivables derecognized, from EUR 178m to EUR 414m. The increase of EUR 236m represents over 80% of the EUR 283m working capital improvement achieved in 2024.

Furthermore, for the first time, there was disclosure of a supplier finance program. These are programs where a financial institution steps in to make payment to suppliers in lieu of the company (usually allowing earlier payment to suppliers). The company then becomes liable to the financial institution, with payment terms which are normally extended relative to standard terms. These payables remain part of the company’s trade payables, so are excluded from net debt. We can see from the disclosure extract below that there were EUR 254m of payables outstanding under the program at the year end. These payables generally had longer payment terms that extended to 6 months.  This was likely a large part of the reason for the increase in trade payables of EUR 115m in 2024, another key driver of working capital improvements.

Taking this all together, it is likely that absent the factoring and supply finance program, working capital would have increased, not decreased in 2024. It would seem then that the “dedicated and focused” actions taken by management revolved mostly around financial engineering rather than operational improvements. Without the support of these programs,

e would have seen a materially different trajectory for cash flow, net debt and gearing. As an illustrative example, if there had been no improvement in working capital, net debt would have been 4.0bn (rather than 3.7bn) and gearing would have risen to 3.3x (rather than 3.0)

If you are an institutional investor, you can sign up to our email list here
arrow icon
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Institutional investors are eligible for a 7-day free trial.

Our machine intelligence helps Portfolio Managers to spot critical red flags hidden deep within the financial statements and governance disclosures.

Request Demo

Forensic Alpha uses proprietary machine intelligence to identify risks hidden deep within the financial statements and governance disclosures.

Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB

Forensic Alpha US INC
12 East 49th Street
New York
NY 10017
USA

forensic alpha
Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB
Forensic Alpha US INC
12 East 49th Street
New York NY 10017
USA
Forensic Alpha Limited is authorised and regulated by the Financial Conduct Authority (Reference number: 763770)
© 2022 Forensic Alpha. All rights reserved.  Terms & Conditions  |  Privacy Policy  |  Cookie policy
twitter profilelinkedin profile